Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02607813
Title	Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
Recruitment	Terminated
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	Advanced Solid Tumor
Therapies	LXH 254 + Spartalizumab LXH 254
Age Groups:	senior \| adult
Covered Countries	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CAN